Search
Why insourcing dermatology services gives commissioners control when pressure is uneven
Dermatology pressure is rarely uniform. Across systems, the challenges sit in different places at different times. Some trusts struggle to protect urgent two‑week‑wait skin cancer pathways. Others carry large routine backlogs that have built up over several years. Many experience both, often compounded by seasonal surges that bring sudden increases in referral volume.
From a clinical perspective, this unevenness matters. When pressure is distributed differently across skin pathways, a single solution is rarely effective. What commissioners need is the ability to respond to where demand is greatest, without destabilising existing services or increasing clinical risk.
This is where well‑designed dermatology insourcing can add real value.
Skin pathway pressure needs targeted capacity
Skin pathways are particularly sensitive to imbalance. Urgent suspected cancer referrals must move quickly, yet they sit alongside large volumes of routine and lower‑risk cases that still require specialist assessment and management.
When routine activity overwhelms clinics, urgent capacity is diluted. When cancer pathways dominate, routine care stalls and waiting lists grow. In both situations, consultants are forced to prioritise later in the pathway than is ideal, often when volume and complexity are already high.
Insourcing can support services at these pressure points, but only when it is deployed deliberately. In practice, this means targeting capacity at specific parts of the pathway rather than simply adding activity. It might involve supporting routine clinics to reduce backlog while protecting two‑week‑wait capacity or stepping into secondary care settings to deliver additional lists alongside NHS teams during periods of peak demand.
When used in this way, insourcing gives commissioners a degree of control that is difficult to achieve through fixed models alone.
Integration matters more than activity
From my experience working across insourced dermatology services at Xyla, what differentiates effective insourcing from short‑term fixes is integration.
Insourced services work best when they are clinically aligned with local pathways and operate to the same standards as substantive NHS services. That starts with clarity at the point of commissioning. A clear service specification that sets out clinical scope, escalation routes and quality expectations avoids ambiguity once services are live.
It continues through mobilisation. Insourcing is not something that can simply be switched on. Services that perform well are those with a planned implementation phase, where operational processes, local policies and reporting arrangements are clearly defined and agreed in advance with the trust.
In practice, this often takes the form of a jointly developed operational manual that translates the contract into day‑to‑day reality. This becomes particularly important when services operate alongside existing NHS clinics, ensuring consistency for patients and clinicians.
Maintaining quality in a risk‑sensitive specialty
Dermatology is a risk‑sensitive specialty. Insourcing should strengthen clinical decision‑making, not dilute it.
For this reason, effective commissioning looks beyond availability alone. Reviewing consultant CVs, specialist experience and relevant outcome data helps ensure that additional capacity brings the right level of expertise into the pathway. This is especially important when services are supporting urgent suspected cancer activity or high‑volume clinics.
Equally important is visible clinical leadership. In effective insourcing models, named clinical leads are in place on both sides of the arrangement, with ongoing clinical‑to‑clinical communication. This supports escalation, maintains consistency and allows emerging issues to be addressed early rather than retrospectively.
Through my role as clinical lead for dermatology at Xyla, responsibility spans safety, audit, guideline adherence and accountability across insourced clinics, teledermatology and face‑to‑face services. This continuity allows capacity to flex without losing grip on governance or patient safety.
Protecting urgent cancer pathways while addressing backlog
One of the greatest concerns for commissioners is how to maintain grip on skin cancer pathways while tackling routine backlog.
Well‑commissioned insourcing can help manage this tension. By absorbing targeted portions of routine or urgent non‑cancer activity, pressure is taken off core clinics, allowing two‑week‑wait pathways to function as intended. When consultants work to agreed triage and escalation protocols, suspected cancers continue to move quickly even during periods of peak demand.
This challenge reflects wider system pressures described in Xyla’s National Cancer Plan executive briefing, which highlights how rising cancer demand and constrained specialist capacity require targeted, well‑governed use of additional capacity. Protecting urgent diagnostic pathways while managing routine backlog depends on where and how capacity is applied, not simply how much is added.
At Frimley ICB, this principle was applied in practice through a consultant‑led teledermatology and insourced dermatology pathway. By enabling early specialist triage and absorbing appropriate activity outside secondary care, the system was able to significantly reduce pressure on urgent pathways while managing a substantial routine backlog.
This approach reflects a key principle that not all referrals need the same response at the same time, but all require consistent clinical oversight.
Governance enables flexibility, not the other way around
Flexibility without governance creates risk. Governance enables flexibility.
In practice, effective insourcing arrangements have clear quality assurance frameworks built in from the outset. Audit, peer review and transparent reporting sit alongside delivery, not after it. Commissioners should also expect clarity on workforce models, including zero tolerance for disguised agency staffing that undermines continuity and accountability.
When these structures are in place, services are better able to scale up or down as demand changes, respond to seasonal surges and support local teams without introducing fragmentation.
What this means for commissioners
For commissioners, the value of dermatology insourcing lies not in adding generic capacity, but in gaining control over where and how that capacity is applied.
When commissioned against clear standards, integrated into local pathways and underpinned by strong clinical leadership, insourced services can relieve specific pressure points across skin pathways, protect urgent suspected cancer capacity, support NHS teams during periods of high demand and maintain consistent quality and patient experience.
In dermatology, good insourcing is less about filling clinics and more about maintaining grip when pressure is uneven.
To discuss how insourced dermatology services can support local skin pathways while maintaining clear clinical governance and accountability, speak to the Xyla dermatology team.
Learn more about our clinically led governance that we embed across all of our services
Related Stories
Share this article
Contact us
Have any questions about our services? Whether you’re wondering about how we can help your health goals, or assist your healthcare organisation, we’d love to hear from you.
Get in touch